Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 31 Aug 2022

van Rensburg Roland, Nightingale Sam, Brey Naeem, Albertyn Christine H, Kellermann Tracy A, Taljaard Jantjie J, Esterhuizen Tonya M, Sinxadi Phumla Z, Decloedt Eric H

Abstract excerpt

BACKGROUND: The late-onset efavirenz neurotoxicity syndrome (LENS) presents as ataxia and/or encephalopathy with supratherapeutic efavirenz plasma concentrations (>4 µg/mL). Efavirenz is primarily metabolized by cytochrome P450 2B6 (CYP2B6), with CYP2A6 as an accessory pathway. We hypothesized that participants with LENS would predominantly be CYP2B6 slow metabolizers. The aim of our study was to determine the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arylamine N-Acetyltransferase

Share to Benzoxazines

Share to Cyclopropanes

Share to Cytochrome P-450 CYP2B6

Share to Isoniazid

Share to Neurotoxicity Syndromes

Source

Identifiers

PMID: 34882770
DOI: 10.1093/cid/ciab961

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).PMID 34882770Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Semantic proximity Read ↗

Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Semantic proximity Read ↗

Efavirenz intoxication due to slow hepatic metabolism.Semantic proximity Read ↗

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Semantic proximity Read ↗

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.Semantic proximity Read ↗

Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.Semantic proximity Read ↗

Efavirenz in the therapy of HIV infectionSemantic proximity Read ↗

Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China.Semantic proximity Read ↗

Efavirenz and the CNS: what we already know and questions that need to be answered.Semantic proximity Read ↗

Impact of pharmacogenetics on CNS side effects related to efavirenz.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.